Orion Oyj

HEL-ORNBV
Nasdaq Helsinki
Healthcare Drug Manufacturers - General
Global Rank
#1871
Country Rank
#10
Market Cap
$10.44 B
Price
$74.94
Change (%)
0.95%
Volume
20,483

Orion Oyj's latest marketcap:

$10.44 B

As of 06/30/2025, Orion Oyj's market capitalization has reached $10.44 B. According to our data, Orion Oyj is the 1871th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap $10.44 B
Revenue (ttm) $1.86 B
Net Income (ttm) $407.08 M
Shares Out 140.69 M
EPS (ttm) $2.9
Forward PE 22.64
Ex-Dividend Date 10/15/2025
Earnings Date 07/18/2025
Market Cap Chart
Data Updated: 06/30/2025

Orion Oyj's yearly market capitalization.

Orion Oyj has seen its market value grow from €3.6 B to €10.44 B since 2014, representing a total increase of 190.31% and an annual compound growth rate (CAGR) of 10.68%.
Date Market Cap Change (%) Global Rank
06/30/2025 €10.44 B 48.35% 1871
12/30/2024 €6 B 8.99% 2523
12/29/2023 €5.51 B -23.26% 2457
12/30/2022 €7.18 B 40.25% 1860
12/30/2021 €5.12 B -2.82% 2834
12/30/2020 €5.27 B -8.98% 2335
12/30/2019 €5.79 B 35.8% 1935
12/28/2018 €4.26 B -3.29% 2059
12/29/2017 €4.41 B -25.88% 2240
12/30/2016 €5.94 B 32.18% 1577

Company Profile

About Orion Oyj

Orion Oyj is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Headquartered in Espoo, Finland, the company operates globally, serving markets in Scandinavia, Europe, North America, and beyond.

Key Products & Services

  • Human Pharmaceuticals: Includes treatments such as:
    • Nubeqa (prostate cancer)
    • Entacapone, Stalevo, Comtess, Comtan (Parkinson's disease)
    • Burana (inflammatory pain)
    • Divina series (menopausal symptoms)
    • Simdax (acute decompensated heart failure)
    • Fareston (breast cancer)
    • Trexan (rheumatoid arthritis and cancer)
    • Dexdor, Precedex, Dexmedetomidine (human sedation)
  • Asthma & COPD Treatments: Easyhaler product line, including Salmeterol/fluticasone, Budesonide/formoterol, and others.
  • Veterinary Drugs: Bonqat, Clevor, Domosedan, Sileo, and Tessie, among others.
  • APIs & Contract Manufacturing: Supplies generic compounds and proprietary APIs, along with manufacturing services.

Strategic Collaborations

Orion Oyj has partnered with Invenra to develop bispecific antibody cancer therapeutics and collaborates with Abilita Therapeutics on innovative antibody therapeutics.

Founded: 1917 | Headquarters: Espoo, Finland

Frequently Asked Questions

  • What is Orion Oyj's (HEL-ORNBV) current market cap?
    As of 06/30/2025, Orion Oyj (including the parent company, if applicable) has an estimated market capitalization of $10.44 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Orion Oyj global market capitalization ranking is approximately 1871 as of 06/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.